COVID-19 antiviral pill jointly developed by U.S.-based Merck and Ridgeback Biotherapeutics, in a boost to the fight against the pandemic.Britain’s Medicines and Healthcare products Regulatory Agency (MHRA) recommended the drug, molnupiravir, be used as soon as possible following a positive COVID-19 test and within five days of the onset of symptoms, citing clinical data.
Experimental pill fights COVID-19, drug-maker Merck claims This is the first oral antiviral treatment for COVID-19 to get approved, with the green light coming ahead of potential U.S.